STOCK TITAN

RELY (NASDAQ: RELY) affiliate reports two 10b5-1 sales of 10,000 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

The company affiliate filed a Form 144 disclosing proposed sales tied to Restricted Stock Units and 10b5-1 plans. The filing lists 16,000 RSU-related shares and two 10b5-1 sales: 10,000 on 04/01/2026 for $152,591.25 and 10,000 on 04/17/2026 for $200,000.

Positive

  • None.

Negative

  • None.
Form type Form 144 SEC notice of proposed sale
RSU-associated shares 16,000 shares Restricted Stock Units dated 08/25/2023
Sale on 04/01/2026 10,000 shares, $152,591.25 10b5-1 sale reported
Sale on 04/17/2026 10,000 shares, $200,000 10b5-1 sale reported
10b5-1 regulatory
"10b5-1 Sales for PANKAJ SHARMA 401 Union Street"
A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.
Restricted Stock Units financial
"Restricted Stock Units | Issuer | 16000 | 08/25/2023"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Form 144 regulatory
"Filer Information | 144: Filer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did the RELY Form 144 disclose?

The filing discloses proposed sales of RSU-related common stock totaling 16,000 shares. It lists two 10b5-1 sales: 10,000 shares on 04/01/2026 for $152,591.25 and 10,000 shares on 04/17/2026 for $200,000.

Who executed the 10b5-1 sales reported in RELY's Form 144?

The transactions are reported under a 10b5-1 plan for Pankaj Sharma (address shown). The filing lists two executed 10b5-1 sales of 10,000 shares each on the dates 04/01/2026 and 04/17/2026 with proceeds indicated.

Are the shares tied to Restricted Stock Units (RSUs)?

Yes. The filing references Restricted Stock Units with an issuance date of 08/25/2023 and a total of 16,000 shares associated with the issuer. The RSU grant details are listed alongside the proposed sales.

Does Form 144 report proceeds from the reported sales?

The filing shows proceeds for the two 10b5-1 sales: $152,591.25 for the 04/01/2026 sale and $200,000 for the 04/17/2026 sale. No further allocation of proceeds is provided in the excerpt.